BRAF V600E 突变型低级别神经节胶质瘤中 BRAF 和 MEK 抑制的联合应用。
Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.
机构信息
Department of Medical Oncology, Alfred Health, Melbourne, Victoria, Australia.
Monash University, Melbourne, Victoria, Australia.
出版信息
J Clin Pharm Ther. 2020 Oct;45(5):1172-1174. doi: 10.1111/jcpt.13112. Epub 2020 Jan 27.
WHAT IS KNOWN AND OBJECTIVE
Post-surgical management of low grade gangliogliomas is controversial with paucity of data for the use of chemotherapy. BRAF mutations are present in a number of glioma subtypes and offer an opportunity for treatment with targeted therapy.
CASE SUMMARY
A 32-year-old man with an unresectable, BRAF V600E mutant, WHO grade 1 ganglioglioma is commenced on combination BRAF and MEK inhibition (vemurafenib and cobimetinib). Partial radiological and clinical response was noted after 13 weeks of treatment. Treatment complication with grade 2 skin and liver toxicity was resolved with dose interruption and reduction.
WHAT IS NEW AND CONCLUSION
Combination BRAF and MEK inhibition present a safe and feasible treatment strategy in unresectable BRAF V600E mutant low grade ganglioglioma.
已知和目的
低级别神经节细胞瘤的术后管理存在争议，缺乏化疗使用的数据。BRAF 突变存在于许多神经胶质瘤亚型中，为靶向治疗提供了机会。
病例摘要
一名 32 岁男性患有不可切除的、BRAF V600E 突变型、WHO 分级 1 级神经节细胞瘤，开始接受 BRAF 和 MEK 抑制（vemurafenib 和 cobimetinib）联合治疗。治疗 13 周后，观察到部分影像学和临床反应。治疗并发症为 2 级皮肤和肝脏毒性，通过剂量中断和减少得到解决。
重要发现和结论
不可切除的 BRAF V600E 突变型低级别神经节细胞瘤中，联合 BRAF 和 MEK 抑制是一种安全可行的治疗策略。
Zotero 插件